Plan C? The Plan B Decision and Calls for a Third Class of Drugs
By
Kate Rawson / Email the Author / The RPM Report December 2011, Vol. 8, No. 2
FDA Beat / Word Count: 1961 / Article # 2011500173
Executive Summary
HHS Secretary Sebelius’ decision to overturn FDA’s approval of Plan B for widespread over-the-counter use was disappointing to many drug reviewers inside the agency. But FDA’s Office of New Drugs Director John Jenkins says the move should be used to reopen the debate over whether to create a third class of drugs. And Plan B, he says, might be a perfect place to start.
$85.00
Buy Now
For $85.00, purchase this 1961-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.